ChemMedChem · 2019 · 32 citations · 18 references
PharmacyMedicinal ChemistryPharmacologyAntimicrobial ResistanceDrug DesignDrug DiscoveryAntibacterial PharmacologyAntibacterial ResistanceAntibiotic ResistanceResistance In Gram-positive BacteriaAntibacterial Drug DevelopmentAntibiotic DiscoveryAntimicrobial Drug DevelopmentLipoteichoic Acid BiosynthesisMembrane-active AntibioticsNovel Antibacterial AgentsNovel Antibacterial Drug Discovery
Abstract The rise of antibiotic resistance, especially in Staphylococcus aureus , and the increasing death rate due to multiresistant bacteria have been well documented. The need for new chemical entities and/or the identification of novel targets for antibacterial drug development is high. Lipoteichoic acid (LTA), a membrane‐attached anionic polymer, is important for the growth and virulence of many Gram‐positive bacteria, and interest has been high in the discovery of LTA biosynthesis inhibitors. Thus far, only a handful of LTA biosynthesis inhibitors have been described with moderate (MIC=5.34 μg mL −1 ) to low (MIC=1024 μg mL −1 ) activities against S. aureus . Herein we describe the identification of novel compounds that potently inhibit LTA biosynthesis in S. aureus , displaying impressive antibacterial activities (MIC as low as 0.25 μg mL −1 ) against methicillin‐resistant S. aureus (MRSA). Under similar in vitro assay conditions, these compounds are 4‐fold more potent than vancomycin and 8‐fold more potent than linezolid against MRSA.
18